TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Allarity Therapeutics
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

Allarity Therapeutics reported significant progress with stenoparib, receiving FDA Fast Track designation for advanced ovarian cancer and presenting clinical trial data showing median overall survival exceeding 25 months for patients receiving the drug twice daily.

Insights
ALLR   positive

Company achieved FDA Fast Track designation, reported promising clinical trial results with median overall survival exceeding 25 months, expanded DRP platform through licensing agreement, and maintained solid financial position through Q4 2026